Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
filgrastim + trastuzumab + vinorelbine
- Development stage
- Discontinued
- Lead developer
- SWOG Cancer Research Network
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Subcutaneous, Intravenous
01
Overview
A combination chemotherapy regimen consisting of filgrastim (G-CSF), trastuzumab, and vinorelbine. This regimen is primarily used for HER2-positive metastatic breast cancer. Trastuzumab targets HER2-overexpressing cancer cells, vinorelbine prevents cancer cell division by inhibiting microtubules, and filgrastim supports immune system recovery by stimulating white blood cell production, allowing for higher chemotherapy dose intensity.
02
Targets
CSF3R (Granulocyte colony-stimulating factor receptor)ERBB2 (Erb-b2 receptor tyrosine kinase 2)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on filgrastim + trastuzumab + vinorelbine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on filgrastim + trastuzumab + vinorelbine.